CA2370570A1 - Adn codant le recepteur humain des vanilloides vr1 - Google Patents

Adn codant le recepteur humain des vanilloides vr1 Download PDF

Info

Publication number
CA2370570A1
CA2370570A1 CA002370570A CA2370570A CA2370570A1 CA 2370570 A1 CA2370570 A1 CA 2370570A1 CA 002370570 A CA002370570 A CA 002370570A CA 2370570 A CA2370570 A CA 2370570A CA 2370570 A1 CA2370570 A1 CA 2370570A1
Authority
CA
Canada
Prior art keywords
receptor
human
protein
dna
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002370570A
Other languages
English (en)
Inventor
Adrienne Dubin
Mark Erlander
Kathryn E. Rogers
Arne Huvar
Rene Huvar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of CA2370570A1 publication Critical patent/CA2370570A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)

Abstract

Dans cette invention, on a cloné et caractérisé l'ADN codant les récepteurs humains des vanilloïdes VR1. La protéine recombinante est capable de former une protéine biologiquement active. Les ADNc ont été exprimés dans des cellules hôtes recombinantes qui produisent la protéine active recombinante. La protéine recombinante est également purifiée à partir des cellules hôtes recombinantes. En outre, les cellules hôtes recombinantes sont utilisées pour mettre en oeuvre un procédé destiné à identifier les modulateurs de l'activité du récepteur, et l'on identifie les modulateurs du récepteur.
CA002370570A 1999-04-15 2000-04-13 Adn codant le recepteur humain des vanilloides vr1 Abandoned CA2370570A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29270099A 1999-04-15 1999-04-15
US09/292,700 1999-04-15
PCT/US2000/009897 WO2000063415A1 (fr) 1999-04-15 2000-04-13 Adn codant le recepteur humain des vanilloides vr1

Publications (1)

Publication Number Publication Date
CA2370570A1 true CA2370570A1 (fr) 2000-10-26

Family

ID=23125812

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002370570A Abandoned CA2370570A1 (fr) 1999-04-15 2000-04-13 Adn codant le recepteur humain des vanilloides vr1

Country Status (5)

Country Link
EP (1) EP1175504A4 (fr)
JP (1) JP2003520022A (fr)
AU (1) AU4237400A (fr)
CA (1) CA2370570A1 (fr)
WO (1) WO2000063415A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009140A1 (fr) 1997-08-20 1999-02-25 The Regents Of The University Of California Sequences nucleotidiques codant pour le recepteur de la capsicine, polypeptides lies au recepteur de la capsicine et leur utilisation
GB9907097D0 (en) 1999-03-26 1999-05-19 Novartis Ag Organic compounds
US6482611B1 (en) 1999-09-23 2002-11-19 Neurogen Corporation Human capsaicin receptor and uses thereof
EP1170365A1 (fr) * 2000-07-04 2002-01-09 Smithkline Beecham Plc Un membre de la famille des polypeptides de canal ionique; vanilrep4
AU2001295531A1 (en) 2000-09-02 2002-03-13 Grünenthal GmbH Antisense oligonucleotides against vanilloid receptor 1
DE10043674A1 (de) * 2000-09-02 2002-03-21 Gruenenthal Gmbh Antisense Oligonukleotide
GB0128161D0 (en) * 2001-11-23 2002-01-16 Merck Sharp & Dohme Receptor protein
MX2007000480A (es) 2004-07-15 2007-03-29 Japan Tobacco Inc Compuesto de benzamida fusionado e inhibidor de actividad de receptor de vainilloide 1.
US7906508B2 (en) 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
GB201918103D0 (en) 2019-12-10 2020-01-22 Oblique Therapeutics Ab Epitopes and antibodies
CN111455470A (zh) * 2020-04-09 2020-07-28 嘉兴菲沙基因信息有限公司 一种可以提升Hi-C文库数据质量的小片段DNA文库构建方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009140A1 (fr) * 1997-08-20 1999-02-25 The Regents Of The University Of California Sequences nucleotidiques codant pour le recepteur de la capsicine, polypeptides lies au recepteur de la capsicine et leur utilisation
CA2309903C (fr) * 1998-01-22 2012-03-27 The Regents Of The University Of California Sequences nucleotidiques codant le recepteur de la capsaicine
EP0943683A1 (fr) * 1998-03-10 1999-09-22 Smithkline Beecham Plc Homologue humain du récepteur vanilloide Vanilrep1

Also Published As

Publication number Publication date
WO2000063415A8 (fr) 2001-01-18
JP2003520022A (ja) 2003-07-02
AU4237400A (en) 2000-11-02
WO2000063415A1 (fr) 2000-10-26
EP1175504A1 (fr) 2002-01-30
EP1175504A4 (fr) 2002-07-31

Similar Documents

Publication Publication Date Title
CA2370570A1 (fr) Adn codant le recepteur humain des vanilloides vr1
US6358706B1 (en) DNA encoding human alpha1G-C T-Type calcium channel
US7179604B2 (en) Methods of use of DNA encoding a human histamine receptor of the H3 subtype
US7094877B2 (en) Human vanilloid receptor VR3 protein
EP1035856B1 (fr) Adn isole codant pour un recepteur h3 d'histamine humain
AU776347B2 (en) DNA encoding a human subunit 5-HT3-C of the 5-HT3 serotonin receptor
US7820792B2 (en) CDNA encoding the human α2 δ4 calcium channel subunit
US6548270B1 (en) DNA encoding human acid-sensing ion channel BNaC4 (ASIC4)
EP1451225A1 (fr) Agonistes pour recepteur de l'histamine h3 recombine humain
AU2001238176A1 (en) DNA encoding human acid-sensing ion channel BNaC4 (ASIC4)
HK1028566B (en) Isolated dna encoding human h3 histamine receptor

Legal Events

Date Code Title Description
FZDE Dead